Paraganglioma

Summary

Paraganglioma (MONDO:0000448) is a disease (an umbrella term covering 12 Mondo subtypes) with 3 cohort genes and 77 clinical trials. The dominant Reactome pathway is Maturation of TCA enzymes and regulation of TCA cycle (3 cohort genes). Top therapeutic interventions include phenoxybenzamine, edotreotide gallium ga-68, and cabozantinib.

At a glance

• Umbrella term: 12 Mondo subtypes
• Cohort genes: 3
• ClinVar variants: 7
• Clinical trials: 77

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paraganglioma
Mondo ID	MONDO:0000448
EFO	EFO:1000453
MeSH	D010235
DOID	DOID:0050773
NCIT	C3308
SNOMED CT	127027008
UMLS	C0030421
MedGen	10571
GARD	0022770
Anatomy (UBERON)	UBERON:0002410
Is cancer (heuristic)	no

Also known as: chemodectoma · neoplasm of paraganglion · neoplasm of the paraganglion · paraganglioma · paragangliomas · paraganglion neoplasm · paraganglion tumor · paraganglion tumour · Paraganglionic neoplasm · Paraganglionic tumor · Paraganglionic tumour · tumor of paraganglion · tumor of the paraganglion · tumour of paraganglion · tumour of the paraganglion

Data availability: 7 ClinVar variants · 11 intOGen driver records.

Disease family

An umbrella term covering 12 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic nervous system neoplasm › paraganglioma

Related subtypes (2): sympathetic neurilemmoma, ganglioneuroma

Subtypes (12): head and neck paraganglioma, pheochromocytoma/paraganglioma syndrome 4, pheochromocytoma/paraganglioma syndrome 1, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 3, pheochromocytoma/paraganglioma syndrome 5, sporadic pheochromocytoma/secreting paraganglioma, non-secreting paraganglioma, parasympathetic paraganglioma, sympathetic paraganglioma, pheochromocytoma/paraganglioma syndrome 6, pheochromocytoma/paraganglioma syndrome 7

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

7 retrieved; paginated sample, class counts are floors:

3 pathogenic/likely pathogenic, 2 conflicting classifications of pathogenicity, 1 benign/likely benign, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
239647	NM_004168.4(SDHA):c.1432_1432+1del	SDHA	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1687624	NM_003000.3(SDHB):c.206G>T (p.Gly69Val)	SDHB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
231390	NM_003002.4(SDHD):c.147dup (p.His50fs)	SDHD	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
428929	NM_003000.3(SDHB):c.744C>G (p.Asn248Lys)	SDHB	Likely pathogenic	criteria provided, multiple submitters, no conflicts
472322	NM_004168.4(SDHA):c.1334C>T (p.Ser445Leu)	SDHA	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1687625	NM_003002.4(SDHD):c.242C>G (p.Pro81Arg)	SDHD	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
36768	NM_003000.3(SDHB):c.32G>A (p.Arg11His)	SDHB	Benign/Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 19 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SDHB	Orphanet:139411	Carney triad
SDHB	Orphanet:201	Cowden syndrome
SDHB	Orphanet:276621	Sporadic pheochromocytoma/secreting paraganglioma
SDHB	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
SDHB	Orphanet:3208	Isolated succinate-CoQ reductase deficiency
SDHB	Orphanet:44890	Gastrointestinal stromal tumor
SDHB	Orphanet:97286	Carney-Stratakis syndrome
SDHA	Orphanet:139411	Carney triad
SDHA	Orphanet:154	Familial isolated dilated cardiomyopathy
SDHA	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
SDHA	Orphanet:3208	Isolated succinate-CoQ reductase deficiency
SDHA	Orphanet:44890	Gastrointestinal stromal tumor
SDHA	Orphanet:97286	Carney-Stratakis syndrome
SDHD	Orphanet:100093	Carcinoid syndrome
SDHD	Orphanet:201	Cowden syndrome
SDHD	Orphanet:276621	Sporadic pheochromocytoma/secreting paraganglioma
SDHD	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
SDHD	Orphanet:3208	Isolated succinate-CoQ reductase deficiency
SDHD	Orphanet:97286	Carney-Stratakis syndrome

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SDHB	HGNC:10681	ENSG00000117118	P21912	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial	clinvar,civic_evidence
SDHA	HGNC:10680	ENSG00000073578	P31040	Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	clinvar
SDHD	HGNC:10683	ENSG00000204370	O14521	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SDHB	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial	Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).
SDHA	Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).
SDHD	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial	Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	1	4.0×	0.460
Other/Unknown	2	1.2×	0.587

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SDHB	Enzyme (other)	yes	1.3.5.1	2Fe-2S_ferredoxin-type, Succ_DH/fum_Rdtase_Fe-S, 2Fe2S_fd_BS
SDHA	Other/Unknown	no		FRD_SDH_FAD_BS, FAD-dep_OxRdtase_2_FAD-bd, Succ_DH_flav_su_fwd
SDHD	Other/Unknown	no		CybS, SQR/QFR_C/D

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	2
heart left ventricle	2
cardiac ventricle	1
mucosa of transverse colon	1
jejunal mucosa	1
jejunum	1
rectum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SDHB	293	ubiquitous	marker	heart left ventricle, cardiac ventricle, apex of heart
SDHA	143	ubiquitous	marker	apex of heart, heart left ventricle, mucosa of transverse colon
SDHD	287	ubiquitous	marker	jejunal mucosa, rectum, jejunum

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SDHA	6,141
SDHB	5,471
SDHD	2,229

Intra-cohort edges

A	B	Sources
SDHA	SDHB	biogrid_interaction, intact, string_interaction
SDHA	SDHD	string_interaction
SDHB	SDHD	biogrid_interaction, string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SDHB	P21912	6
SDHA	P31040	5
SDHD	O14521	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Maturation of TCA enzymes and regulation of TCA cycle	3	571.0×	2e-08	SDHB, SDHA, SDHD
Citric acid cycle (TCA cycle)	3	423.0×	3e-08	SDHB, SDHA, SDHD
Respiratory electron transport	3	95.2×	2e-06	SDHB, SDHA, SDHD
Aerobic respiration and respiratory electron transport	2	59.0×	5e-04	SDHB, SDHA
Metabolism	2	7.7×	0.021	SDHB, SDHA

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
mitochondrial electron transport, succinate to ubiquinone	3	3370.4×	1e-10	SDHB, SDHA, SDHD
tricarboxylic acid cycle	3	510.7×	3e-08	SDHB, SDHA, SDHD
proton motive force-driven mitochondrial ATP synthesis	3	263.3×	2e-07	SDHB, SDHA, SDHD
succinate metabolic process	2	2246.9×	5e-07	SDHB, SDHA
respiratory electron transport chain	2	561.7×	7e-06	SDHB, SDHA
regulation of catecholamine secretion	1	5617.3×	3e-04	SDHD
aerobic respiration	1	82.6×	0.016	SDHB
cellular response to hypoxia	1	40.4×	0.028	SDHD
nervous system development	1	15.3×	0.064	SDHA

Therapeutics

Drugs indicated for this disease

0 approved, 16 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Albumin Human	Phase 3 (in late-stage trials)
Aminolevulinic Acid	Phase 3 (in late-stage trials)
Ascorbic Acid	Phase 3 (in late-stage trials)
Bevacizumab	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Carmustine	Phase 3 (in late-stage trials)
Dextroamphetamine	Phase 3 (in late-stage trials)
Dianhydrogalactitol	Phase 3 (in late-stage trials)
Dordaviprone	Phase 3 (in late-stage trials)
Doxazosin	Phase 3 (in late-stage trials)
Lomustine	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Phenoxybenzamine	Phase 3 (in late-stage trials)
Temozolomide	Phase 3 (in late-stage trials)
Tranexamic Acid	Phase 3 (in late-stage trials)
Vorasidenib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): ANG1005, ANTINEOPLASTON A10, Abemaciclib, Afatinib, Avelumab, Axitinib, Azacitidine, Bortezomib, Capecitabine, Celecoxib, Cilengitide, Cisplatin, Copper, Crenolanib, Dasatinib Anhydrous, Disulfiram, Doxorubicin, Edotreotide, Epacadostat, Etoposide, Everolimus, Infigratinib, Influenza Virus Vaccine, Iobenguane, Irinotecan, Ivosidenib, Keyhole Limpet Hemocyanin, Lacosamide, Lanreotide, Lapatinib, Lenvatinib, Levetiracetam, Marizomib, Mirtazapine, Nilotinib, Nimotuzumab, Nivolumab, PEGINTERFERON ALFA-2B, Pazopanib, Pembrolizumab, Penpulimab, Retifanlimab, Rivoceranib, Selinexor, Sirolimus, Tetanus Toxoid, Thalidomide, Tipifarnib, Vinblastine, Vismodegib.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SDHA	LINEZOLID

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SDHA	1	4
SDHB	0	0
SDHD	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
LINEZOLID	4	SDHA

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SDHB	4	Binding:4
SDHA	3	Binding:3

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
SDHB	1.3.5.1	succinate dehydrogenase

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
LINEZOLID	4	SDHA

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	SDHA
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	SDHB
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	SDHD

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SDHB	4	SDHA
SDHD	0	SDHA

Clinical trials & evidence

Clinical trials

Clinical trials: 77.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	34
PHASE2	25
PHASE1/PHASE2	7
PHASE1	5
PHASE4	2
PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04081701	PHASE4	RECRUITING	68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
NCT05702944	PHASE4	RECRUITING	The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
NCT01373736	PHASE3	UNKNOWN	123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
NCT03176693	PHASE3	COMPLETED	Preoperative Alpha Blockade for Pheochromocytoma
NCT02721732	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03206060	PHASE2	RECRUITING	Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
NCT03839498	PHASE2	ACTIVE_NOT_RECRUITING	Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
NCT03946527	PHASE2	ACTIVE_NOT_RECRUITING	LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
NCT04394858	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
NCT04711135	PHASE2	ACTIVE_NOT_RECRUITING	Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT05142241	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
NCT05636618	PHASE1/PHASE2	RECRUITING	Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT06045260	PHASE2	RECRUITING	Receptor Radionuclide Therapy With 177Lu-DOTATOC
NCT06121271	PHASE2	NOT_YET_RECRUITING	Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
NCT06427798	PHASE1/PHASE2	RECRUITING	Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
NCT06607692	PHASE1/PHASE2	RECRUITING	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
NCT00458952	PHASE1/PHASE2	COMPLETED	Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
NCT00843037	PHASE2	COMPLETED	Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
NCT00874614	PHASE2	UNKNOWN	A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
NCT01340794	PHASE2	TERMINATED	Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
NCT01413503	PHASE2	COMPLETED	A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
NCT01560260	PHASE2	COMPLETED	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
NCT01635907	PHASE2	COMPLETED	Dovitinib in Neuroendocrine Tumors
NCT01967576	PHASE2	COMPLETED	Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
NCT02177773	PHASE1/PHASE2	TERMINATED	GA-68 DOTA-TOC of Somatostatin Positive Malignancies
NCT02302833	PHASE2	COMPLETED	Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
NCT03165721	PHASE2	TERMINATED	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
NCT03923257	PHASE1/PHASE2	WITHDRAWN	Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
NCT04106843	PHASE2	WITHDRAWN	Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
NCT04187404	PHASE1/PHASE2	TERMINATED	A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
NCT04276597	PHASE2	WITHDRAWN	Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
NCT04400474	PHASE2	COMPLETED	Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
NCT05883085	PHASE2	UNKNOWN	A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
NCT05885386	PHASE2	UNKNOWN	A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
NCT06233903	PHASE2	WITHDRAWN	18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
NCT04119024	PHASE1	RECRUITING	Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT00339131	PHASE1	COMPLETED	ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
NCT01155258	PHASE1	COMPLETED	Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT01204476	PHASE1	COMPLETED	Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PHENOXYBENZAMINE	4	6
EDOTREOTIDE GALLIUM GA-68	4	5
CABOZANTINIB	4	3
DOXAZOSIN	4	3
LUTETIUM OXODOTREOTIDE LU-177	4	3
AXITINIB	4	2
IOBENGUANE I 131	4	2
LANREOTIDE	4	1
OCTREOTIDE ACETATE	4	1
PAZOPANIB HYDROCHLORIDE	4	1
PIFLUFOLASTAT F18	4	1
VANDETANIB	4	1
FLORBENGUANE F18	3	2
CATEQUENTINIB HYDROCHLORIDE	3	1
DOVITINIB	3	1
GUADECITABINE	3	1
LINSITINIB	3	1
LUTETIUM LU177 EDOTREOTIDE	2	2
CIXUTUMUMAB	2	1
TIGOZERTINIB	2	1
CHEMBL3939307	0	2
CHEMBL275117	0	1
CHEMBL4517714	0	1
CHEMBL5405436	0	1
CHEMBL4578973	0	1
CHEMBL3764816	0	1
CHEMBL5724798	0	1
CHEMBL5572229	0	1